New clinical data shows Prolacta Bioscience's exclusive human milk diet correlates with a 20% reduction in mortality for premature infants, strengthening the company's clinical profile.
A meta-analysis showing Prolacta's exclusive human milk diet is associated with 20% lower odds of death in premature infants could enhance the company's clinical credibility and commercial adoption.
A new meta-analysis published in Frontiers in Nutrition reveals that Prolacta Bioscience's exclusive human milk diet is associated with a 20% lower risk of mortality in premature infants. The study, which pooled data from 14 clinical trials involving 4,713 infants, provides significant clinical validation for the company's nutritional products.
The study indicates that infants fed an exclusive human milk diet have 20% lower odds of mortality before hospital discharge compared to those who do not.